Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Merck and Co's cancer drug Keytruda to smash sales records by 2023 ...
Merck: KEYTRUDA And GARDASIL Sales Are Expected To Rise (NYSE:MRK ...
Merck's quarterly Keytruda sales soar past $3B, but analysts fret over ...
Merck's cancer drug Keytruda on pace for $17 billion of sales
Merck posts strong Q1 sales helped by Keytruda | AlphaStreet
Keytruda Sales Climb 16 Percent in Q2 as Merck Pursues New Oncology ...
Merck highlights subcutaneous demand even as Keytruda sales soar | Dr ...
Merck Talks Up Pipeline Diversification as Keytruda Sales Still ...
Keytruda Sales Market Report | Global Forecast From 2025 To 2033
Merck tops profit estimates on Keytruda sales
Merck Stock Climbs After Higher-Than-Expected Sales of Cancer Drug Keytruda
Merck profit soars 61.5 pct as Keytruda sales surge | Fox Business
Merck in Charts: KEYTRUDA sales surge 9% Y/Y, GARDASIL dips 54% in Q2
Keytruda sales power Merck to quarterly beat
Merck’s Keytruda tops drug sales in Korea | The Korea Herald
Will Higher Keytruda Sales Drive Merck's Q1
- Cancer Drug Keytruda Sees 20% Q3 Sales Increase for Merck - via ...
Merck's Keytruda Drives Record Profits Amid Revised Sales Projections ...
Merck’s Keytruda sales eclipse $18B on the year, while numbers for ...
Merck: Keytruda’s Sales Projections Outweigh Competitive And Patent ...
Merck Q2 2025 slides: KEYTRUDA growth offsets GARDASIL decline ...
Keytruda Market Size, Share, Growth | Industry Report, 2030
Top Pharma Companies & Drugs in 2024: Merck’s Keytruda maintains top ...
FDA approves Merck’s Keytruda for advanced NSC lung cancer - Pharmafile
NICE approval for Keytruda a 'milestone' in lung cancer | pharmaphorum
Approval of Keytruda in Europe for first-line use with chemotherapy in ...
Merck & Co. 2024: Keytruda takes over - PharmaLive
Merck agrees to resolve Keytruda patent infringement litigation ...
Keytruda Could Significantly Drive Merck’s Revenue Growth
Merck’s Keytruda could offer ‘paradigm shift’ in lung cancer treatment
Merck's PD-1 Inhibitor Keytruda Approved by NMPA for Cervical Cancer ...
Merck plans to launch US subcutaneous version of Keytruda on October 1 ...
Merck's cancer drug Keytruda succeeds in a late-stage trial
Keytruda Combination Therapy Approved as First-Line Treatment of ...
Merck gets FDA approval for subcutaneous Keytruda | Leonard Joseph ...
Merck 's China Business Surges, Keytruda Soars Globally with $14.2 ...
Two new EC approvals for Merck’s Keytruda | Biotechnology | The ...
FDA Approves Merck's Keytruda Combo for Early Breast Cancer Treatment ...
Merck's Keytruda Expands into Cervical Cancer in Canada: A Strategic ...
Why Should You Not Ignore Merck And Keytruda In 2017? (NYSE:MRK ...
Merck’s Keytruda Will Become Best-Selling Drug Worldwide, Research ...
Keytruda Merck: Νέα ασιατική δοκιμή με θετικό πρόσημο για το Keytruda ...
Merck's Keytruda Expansion Shakes Up Cancer Treatment Landscape
Keytruda Pivotal For Merck's Revenues, Diversification Strat
Merck’s Keytruda Is the World’s Largest Drug. The Race Is On to Replace ...
Merck: Keytruda Growth Remains Strong
FDA Approves Merck’s keytruda Combo for Early Breast Cancer - YouTube
Biggest blockbuster drugs of 2020 : Drug sales and beyond ...
Merck / Keytruda Brand Advance | Behance
Dr Mridul Das on LinkedIn: 💰 Merck Beats Profit Projections as Keytruda ...
KEYTRUDA (Merck Sharp & Dohme LLC): FDA Package Insert
Merck beats earnings expectations, raises outlook on strong Keytruda ...
Keytruda drug: Uses, indications and notes when using | Vinmec
FDA Suspends Certain Clinical Trials of Merck’s Keytruda - WSJ
Merck’s Keytruda sales; Valeant on name change; Pfizer – BMS
Keytruda revenue 2025| Statista
MSD’s Keytruda expands reach in lung cancer with neoadjuvant setting ...
PHARMA JONPI .: KEYTRUDA BY MERCK ( PEMBROLIZUMAB ) Podría Perder ...
Merck Seeks FDA Approval for Keytruda as First-Line Treatment - Drug ...
Merck Speeds Up Launch of New Keytruda Version as Patent Expiration ...
Keytruda 25mg/ml Merck (Hộp 1 lọ x 4ml)
Merck's Keytruda combo gets FDA nod for expanded use in cervical cancer ...
Keytruda Qlex FDA Approval: A Guide to Subcutaneous Pembrolizumab ...
Merck Keytruda and Eisai Lenvima Achieve Triple Approval In Oncology ...
Keytruda Qlex Wins FDA Approval, Enabling One- to Two-Minute ...
Keytruda Market Size, Trends, Growth Report 2035
Merck’s KEYTRUDA receives approval in China
Merck & Co. sees animal health unit as counterweight to Keytruda ...
Merck’s Subcutaneous Keytruda Meets Expectations in Phase III - BioSpace
Citing "Strong Sales," Pension Manager Buys Partial Keytruda Rights for ...
What Type Of Cancer Is Keytruda Used For - CancerWalls
Keytruda market Size, Trends & Forecast, 2025-2032
Keytruda remains Merck & Co’s biggest 2023 success story as patent ...
Injectable Cancer Drug Keytruda Qlex Gains FDA Approval
Keytruda Market Size, Trends, Growth Report 2034
Keytruda Market Size & Share | Industry Report, 2033
FDA clears subcutaneous Keytruda in a boost to MSD | pharmaphorum
FDA Grants Priority Review to Merck’s Application for KEYTRUDA Plus ...
Merck’s Keytruda lifts survival rates for lung cancer
Keytruda Gets FDA Approval for Hepatocellular Carcinoma - Clinical Advisor
Keytruda Gets FDA Approval for Hepatocellular Carcinoma- Clinical Advisor
Merck: Still Undervalued Considering Keytruda's Prospects | Seeking Alpha
Merck Is Climbing Higher, With Growth Potential (NYSE:MRK) | Seeking Alpha
Merck is broadening its pipeline as Keytruda’s patent cliff looms ...
Merck Receives Accelerated Approval of KEYTRUDA® (pembrolizumab), the ...
Merck's Announcement of Successful Phase 3 Trial of Subcutaneous ...
Merck: A Buy For 2026, But The Clock Is Still Ticking (NYSE:MRK ...
Merck Poised to Revolutionize Cancer Treatment with Innovative ...
Merck Proves Why It’s Still A Top Pharma Pick (NYSE:MRK) | Seeking Alpha
Just A Life Sciences Blog...: Merck's Keytruda® Receives Its Fourth FDA ...
Page 10 – Cancer Therapy Advisor
MERCK: FDA Accepts Merck’s Supplemental Biologics License Applications ...
Merck: Don't Fight The Tape, How Low Can It Go? (NYSE:MRK) | Seeking Alpha
Merck seeks more deals to prepare for Keytruda's revenue decline | Reuters
FDA Approves Keytruda: US FDA approves Merck's injectable version of ...
Merck tiene en clesromimab una oportunidad para crecer
How Keytruda's Latest Approval in China Boosts Merck | citybiz
Keytruda®, Ozempic® and the other blockbuster drugs of the 3rd quarter ...
Heat: Mega-Daten in Sicht - und jetzt auch noch Keytruda!
Pharmaceutical Technology
Keytruda's LOE: Is it the end or the beginning for Merck?
FDA Approves Keytruda's Game-Changing Subcutaneous Formulation: A ...
Blockbuster Cancer: Merck second quarter tops Street view on strong ...
KEYTRUDA® (pembrolizumab) in combination with KISPLYX® (lenvatinib ...
Investing in Nobel Prize Achievements – Immunology To Treat Cancer ...
Just A Life Sciences Blog...: Merck Sees Post-Market Study Outcome ...
Merck's $10 Billion Gamble: Can Respiratory Diversification Offset ...
